| dc.contributor.author | Malatyalioglu E. | |
| dc.contributor.author | Yanik F.F. | |
| dc.date.accessioned | 2020-06-21T09:16:02Z | |
| dc.date.available | 2020-06-21T09:16:02Z | |
| dc.date.issued | 1999 | |
| dc.identifier.issn | 1300-2996 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12712/2844 | |
| dc.description.abstract | Based on elevated MSAFP levels, 85% to 90% of NTDs can be detected. Using a combination of the three parameters, MSAFP, hCG and UE3, 55% to 60% of fetal Down's syndrome can be detected. Future strategies for Down's syndrome screening may include the use of new markers such as dimeric inhibin-A and urinary ?-core fragment of hCG, as well as first-trimester screening, particularly with PAPP-A and free ?-hCG. | en_US |
| dc.language.iso | tur | en_US |
| dc.rights | info:eu-repo/semantics/closedAccess | en_US |
| dc.subject | ?-fetoprotein | en_US |
| dc.subject | Down's syndrome | en_US |
| dc.subject | Human chorionic gonadotropin | en_US |
| dc.subject | Neural tube defects | en_US |
| dc.subject | Triple marker | en_US |
| dc.subject | Unconjugated estriol | en_US |
| dc.title | Maternal serum screening for prenatal diagnosis of some fetal genetic disorders | en_US |
| dc.title.alternative | Bazi Fetal Genetik Hastaliklarin Prenatal Tanisinda Maternal Serum Taramasi | en_US |
| dc.type | article | en_US |
| dc.contributor.department | OMÜ | en_US |
| dc.identifier.volume | 16 | en_US |
| dc.identifier.issue | 1 | en_US |
| dc.identifier.startpage | 76 | en_US |
| dc.identifier.endpage | 85 | en_US |
| dc.relation.journal | Ondokuz Mayis Universitesi Tip Dergisi | en_US |
| dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
